Abstract
In contrast to serial injections of recombinant protein, prolonged systemic delivery of proteins derived through in vivo gene transfer may ultimately provide a favorable alternative for long-term therapy of chronic inflammatory diseases such as the predominant use of interferon-beta (IFNβ) in the treatment of multiple sclerosis (MS). In the current study we compared the therapeutic efficacies of electroporation (EP) mediated intramuscular IFNβ gene transfer with repeated alternate day injections of recombinant IFNβ after onset of experimental autoimmune encephalomyelitis (EAE), an animal model widely used in MS research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
